Enzo Biochem (ENZ) Q3 2025 earnings summary

Executive summary

• Revenues declined 20% year-over-year to $6.4 million for the quarter, reflecting industry headwinds, reduced R&D budgets, and order timing.

• Operating loss for the nine months improved by $1.1 million year-over-year due to cost containment and lower legal expenses.

• The company completed the sale of its clinical services business in July 2023 and now operates solely in the Products segment.

• A strategic review process was initiated in April 2025 to explore potential transactions, including a sale or return of capital.

• Voluntary delisting from NYSE completed in April 2025; shares now trade on OTCQX.

Financial highlights

• Gross margin for the quarter was 39% (41% excluding inventory provision), down from 47% year-over-year.

• Net loss for the quarter was $2.8 million ($0.05 per share), and $7.7 million ($0.15 per share) for the nine months, both improved from prior year losses.

• Cash and cash equivalents were $36.7 million as of April 30, 2025; working capital stood at $31.3 million.

• Net cash used in operating activities was $14.2 million for the nine months, a significant improvement from $25.2 million in the prior year.

• Stockholders' equity was $43.4 million and total assets $63.5 million as of April 30, 2025.

Outlook and guidance

• Management believes current working capital is sufficient for at least the next twelve months.

• Strategic review underway to evaluate potential transactions, business combinations, or capital returns.

• Focus remains on cash conservation and driving revenue from new product launches.